Story perspectives

Sona Nanotech's Therapy Shows Promise in Melanoma Study

4/10/2026

Summary

Story summary

Sona Nanotech Inc. reported positive results from its first-in-human clinical study of Targeted Hyperthermia Therapy (THT) for patients with immunotherapy-resistant cutaneous metastatic melanoma.
Out of ten patients, eight exhibited significant clinical responses, with six showing no detectable melanoma in biopsied tumors within two weeks.
The study also indicated favorable safety data, prompting Sona to plan a Canadian clinical trial to further investigate THT's potential.
Chief Scientific Officer Len Pagliaro will reduce his operational role but remain a board member.
A webinar to discuss these results is scheduled for October 20, 2025.

1 of 1

Story summary

Sona Nanotech Inc. reported positive results from its first-in-human clinical study of Targeted Hyperthermia Therapy (THT) for patients with immunotherapy-resistant cutaneous metastatic melanoma.
Out of ten patients, eight exhibited significant clinical responses, with six showing no detectable melanoma in biopsied tumors within two weeks.
The study also indicated favorable safety data, prompting Sona to plan a Canadian clinical trial to further investigate THT's potential.
Chief Scientific Officer Len Pagliaro will reduce his operational role but remain a board member.
A webinar to discuss these results is scheduled for October 20, 2025.